Antiretroviral Treatment Associated Hyperglycemia And Dyslipidemia Among Hiv Infected Patients At Burayu Health Center Addis Ababa Ethiopia 2012

Introduction: Development of HAART has brought significant suppression of viral replication,rndecreasing morbidity and mortality and dramatically transforming HIV into chronic disease.rnUnfortunately, the prospect of maintaining patients on HAART for long term may be restrictedrnby a heterogeneous collection of unexpected metabolic abnormalities, including dysregulation ofrnglucose metabolism, dyslipidemia and lipodystrophy. rnObjective: To assess antiretroviral treatment associated hyperglycemia and dyslipidemia amongrnHIV infected patients at Burayu Health Center, Addis Ababa, Ethiopia. rnMethodology: A cross-sectional study was conducted on adult HIV infected individuals atrnBurayu Health Center, Addis Ababa, Ethiopia from September, 2011 to May, 2012. Equalrnnumber of HAART naïve and HAART initiated patients (n=126 each) were included in thernstudy. Demographic data were collected using a well-structured questionnaire. TC, TG, HDL-C,rnLDL-C and glucose were determined using COBAS INTERGA 400 chemistry analyzer. Therndata were analyzed using SPSS version 19 software. Chi-square, student-t-test and logisticrnregression were used to assess association between variables. P value < 0.05 was considered asrnstatistically significant.rnResult: Of 252 study participants, 72.2% were females, mean age was 35.3 years; mean BMIrnwas 21.4; mean time with the virus was 20.6 months; 62.7% were married; 48.4% were atrnprimary educational level; 52.4% were house wives; 15.5% were TB-HIV co-infected and 43.7%rnwere categorized as WHO stage one. The prevalence of hyperglycemia, hypertriglyceridemia,rnhypercholesterolemia, decreased HDL-C and increased LDL-C was 7.9%, 22.8%, 42.1%, 50.8%rnand 23% in HAART initiated and 5.6%, 10.3%, 11.1%, 73% and 7.1% in non-HAART groups,rnrespectively. ART regimens observed as a first line were only containing 2 nucleoside backbonesrn(from AZT/D4T/3TC/TDF) with either NVP or EFV. Serum TG level ≥200 mg/dl was morerncommon among patients who received D4T based than those with AZT based antiretroviralsrn(34% versus 16.4%, P = 0.029).rnConclusion: First-line HAART is associated with potentially atherogenic lipid profile levels inrnpatients with HIV infection compared to untreated patients in our setting. This indicates glucose rnand lipid profile levels need to be monitored regularly in HIV infected patients taking rnantiretroviral treatment.

Get Full Work

Report copyright infringement or plagiarism